Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of dalbavancin vs vancomycin + linezolid for acute bacterial skin and skin structure infections
2011-002130-40Phase 3Completed
- Sponsor
- Durata Therapeutics
- Start
- Sep 2011
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dalbavancin in acute bacterial skin and skin structure infection (ABSSSI) and Staphylococcus aureus infection (2 arms), sponsored by Durata Therapeutics. Primary endpoint: Early clinical response at 48–72 hours. Started Sep 2011; status: completed.
02
Drugs
dalbavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)Staphylococcus aureus infection
Beyond the preview
Go deeper on 2011-002130-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002130-40.